Tue, Apr 15, 9:26 PM (11 days ago)
**BioAdaptives, Inc. (BDPT) - Financial Summary** **Financial Performance (in thousands):** - **Revenue:** $12,669 (2024), $28,565 (2023) - **Net Income:** -$899,161 (2024), -$712,466 (2023) - **Operating Expenses:** $606,120 (2024), $239,740 (2023) - **Earnings per Share:** -$0.11 (2024), -$0.12 (2023) **Strategic Overview:** - Core business: Natural plant, fungi, and algal-based products and medical devices for health and wellness. - Key products: Zeranovia™ (weight management), Xcellara™ (stem cell activator), PawPa™ Regen (canine treat), MyndMed™ (nootropic). - Marketing: Direct-to-consumer digital campaigns, telehealth partnerships, affiliate marketing. **Future Outlook:** - New products expected to enter the market in Q1-Q2 2025. - Focus on expanding market presence and driving innovation. **Risk Factors:** - Limited operating history and reliance on external financing. - Competition in the nutraceutical industry. - Regulatory risks and market volatility. **Financial Condition:** - **Assets:** $261,885 (2024), $103,998 (2023) - **Liabilities:** $1,725,803 (2024), $1,750,629 (2023) - **Stockholders' Deficit:** -$1,463,918 (2024), -$1,646,631 (2023) **Market Position Changes:** - **Share Price:** $0.09 (March 21, 2025), $0.06 (December 31, 2024) - **Shares Outstanding:** 9,048,659 (March 21, 2025), 4,107,680 (December 31, 2024) **Key Financial Ratios (2024):** - **Current Ratio:** 0.15 - **Debt-to-Equity:** -1.18 (negative due to stockholders' deficit) - **Gross Margin:** 32.02% **Management and Governance:** - **CEO:** James E. Keener - **Director:** Gimhana Dissanayake - **Board Composition:** 3 members (as of January 2025) - **Audit Committee:** None; functions performed by the entire board. **Notable Events:** - Reverse stock split (1-for-300) completed on November 21, 2024. - Stock dividend (1-for-1) approved on December 3, 2024. **Conclusion:** BioAdaptives, Inc. is a developing company in the nutraceutical industry with a focus on innovative health and wellness products. Despite facing financial challenges and market risks, the company is poised to introduce new products in 2025 and expand its market presence. However, investors should be aware of the company's reliance on external financing and the competitive nature of the industry.